ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle-Mediated Angiogenesis and the NF-κB-PCLAF Signaling Axis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Small intracellular vesicle-liposome fusogenic nanoplatform sIVs-LPs@Hes: Nebulized delivery targeting pulmonary inflammatory microenvironment to improve ALI.Materials today. Bio · 2026Article
- Single-cell analysis identifies a tumor-specific T-cell metabolic signature: prognostic model and association with immunosuppressive microenvironment in ovarian cancer.Translational cancer research · 2026Article
- Tomatine as a versatile adjuvant boosts mRNA vaccine responses.Materials today. Bio · 2025Article
- Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle-Mediated Angiogenesis and the NF-κB-PCLAF Signaling Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Clathrin light chain B (CLTB) is one of the three light chain subunits of the clathrin complex. This study aims to elucidate the role of CLTB in the pathogenesis of hepatocellular carcinoma (HCC) and its clinical implications. Clinical and bioinformatic analyses reveal marked CLTB overexpression in HCC tissues. Genetic silencing of CLTB suppresses HCC cell proliferation, migration, and invasion, whereas its overexpression exacerbates malignant phenotypes. Mechanistically, CLTB activates NF-κB signaling to upregulate PCNA clamp-associated factor (PCLAF), thereby promoting small extracellular vesicle (sEV) uptake. Given that clathrin-mediated endocytosis is the key mechanism for sEV uptake, this study further investigated the functional implications of CLTB-enriched sEVs in tumor vascular remodeling. sEV-CLTB promotes endothelial angiogenesis, disrupts vascular integrity, and induces pulmonary vascular leakage by binding SH3 domain-containing kinase-binding protein 1 (SH3KBP1) and then inhibiting SH3KBP1 ubiquitination degradation. In patient-derived xenograft (PDX) models, combined therapy of clathrin inhibitor (chlorpromazine) or SH3KBP1 silencing with sorafenib suppresses tumor growth and reduces microvascular density. This study demonstrates that CLTB promotes HCC progression through the NF-κB-PCLAF signaling axis and sEV-mediated vascular remodeling, providing a mechanistic foundation for developing combination therapies targeting CLTB.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.